Clinical Trial Company HealthMatch gains A$10 million Series C Funding

Must Read

Australian startup digital platform HealthMatch aids patients by connecting them with the correct clinical trials. Their platform allows researchers to reach a diverse patient population, helping them match the proper individuals to their studies. It also allows patients to recruit faster, avoiding waiting long hours at trial sites.

The company was just founded in 2017 but has already completed more than 3.6 million clinical trial matches and assisted over a million patients globally. Its primary goal is to help patients understand the details of a clinical trial and match them with the correct coordinators, saving them time in the process.

Despite its success, HealthMatch had to downsize its team last June. Founder and CEO Manuri Gunawardena says, “despite our success to date, the changing capital markets meant HealthMatch needed to adjust its approach to scale and make some difficult restructuring decisions earlier this year.”

The company’s standing changed around mid-September. Investment firm Folklore Ventures, a firm focusing on Australian and New Zealand tech companies, invested in HealthMatch and Square Peg Capital. The Series C funding raised amounted to A$10 million.

The new funds are slated to help the company expand its team and platform reach throughout the US to help more Americans gain access to clinical trials. “We have great healthcare in Australia, where access to leading healthcare providers and medicines is publicly available through Medicare.

Unfortunately, this is not the case in the US, and we have seen strong interest in accessing trials, particularly from underserved and diverse communities that aren’t adequately resourced,” Gunawardena adds.

HealthMatch launched in the US just October 2021 but has seen more than 100,000 new registrants month on month, providing more and more opportunities for patients to be matched to specific clinical trials.

HealthMatch’s collaboration with pharmaceutical companies like Roche and AbbVie and biotechnology firms like Imugene and Earli provides a more in-depth insight into patients. This allows the companies to develop better clinical trials to deliver better treatment to patients globally.

- Advertisement -spot_img
Latest News
- Advertisement -spot_img

More Articles Like This

- Advertisement -spot_img